Salute e Benessere
Astraveus Announces World First End-to-End Production of CAR-T Cells Using Microfluidic Technology
The fully automated Lakhesys Benchtop Cell Factory™ integrates the entire cell therapy manufacturing process and onboard analytics into an all-in-one system, harnessing advanced microfluidic technology for optimal cell quality and efficient processing. Through scalable parallelization from pre-clinical to commercial stages, the Lakhesys™ Benchtop Cell Factory drastically reduces cost of goods, minimizes required lab space, and eliminates cell stress throughout the manufacturing process.
"
"
Astraveus is a Paris -based life science company dedicated to making cell therapies with maximized quality at order-of-magnitude lower cost. With the unique Lakhesys Benchtop Cell Factory™, Astraveus provides bioprocessing innovation at the cellular level, utilizing cutting-edge microfluidic technology to enhance process optimization and scalability from pre-clinical to commercial manufacturing.
Founded in 2016 by Jérémie Laurent at the Saint-Louis Hospital in
Paris , a prestigious hub for leading cell therapy research, Astraveus is committed to revolutionize the development and manufacturing of cell therapies and aspires to make these innovative treatments accessible to everyone in need, thereby enabling a healthier tomorrow.
www.astraveus.com
View original content:https://www.prnewswire.co.uk/news-releases/astraveus-announces-world-first-end-to-end-production-of-car-t-cells-using-microfluidic-technology-302346213.html